Any intermittent iron regimen (with or without other vitamins and… showed no clear difference in birthweight (g) compared with daily regimen (with same vitamins and minerals)‐infant outcomes (low certainty).
Any intermittent iron regimen (with or without other vitamins and… showed no clear difference in premature birth (less than 37 weeks of gestation) compared with daily regimen (with same vitamins and minerals)‐infant outcomes (low certainty).
It is very uncertain whether any intermittent iron regimen (with or without other vitamins and… changes neonatal death (within 28 days after delivery) compared with daily regimen (with same vitamins and minerals)‐infant outcomes (very low certainty).
It is very uncertain whether any intermittent iron regimen (with or without other vitamins and… changes maternal anaemia at term (Hb less than 110 g/L at 37 weeks'… compared with daily regimen (with same vitamins and minerals)‐maternal outcomes (very low certainty).
Any intermittent iron regimen (with or without other vitamins and… led to lower maternal death (death while pregnant or within 42 days of… compared with daily regimen (with same vitamins and minerals)‐maternal outcomes; GRADE not reported.
Oral ferric maltol showed no clear difference in number of responders ‐ disease activity not stated (12 weeks) compared with IV ferric carboxymaltose (low certainty).
It is very uncertain whether oral ferric maltol changes serious adverse events (12 weeks) compared with IV ferric carboxymaltose (very low certainty).
Dextrose gel showed no clear difference in separation from mother for treatment of hypoglycaemia (infant nursed… compared with placebo (low certainty).
IV ferric carboxymaltose showed no clear difference in number of responders ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (low certainty).
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).
The intervention probably leads to lower low Hb deferral ‐ at first donation visit after commencement of… (moderate certainty).
The intervention probably leads to lower low Hb deferral ‐ after multiple donation visits (moderate certainty).
The intervention probably leads to higher adverse effects (any) (moderate certainty).
It is very uncertain whether IM erythropoietin changes number of responders ‐ active disease (12 weeks) compared with oral placebo (very low certainty).
The review found no eligible studies for this question.